IRVINE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc., (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of
therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a